Post-Essential Thrombocythemia Myelofibrosis clinical trials in New York
5 active Post-Essential Thrombocythemia Myelofibrosis trials with a site in New York. Describe your situation to see which ones look like a fit.
- A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- Revumenib in Patients With Myelofibrosis
- Study of Canakinumab in Patients With Myelofibrosis
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.